文献速递慢性静脉疾病

专用静脉支架治疗慢性深静脉疾病的 Medium- to Long-term 结局:一项 Meta 分析

A meta-analysis of the medium- to long-term outcomes in patients with chronic deep venous disease treated with dedicated venous stents.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2023-12-15

该系统评价与 Meta 分析检索 2010 年 1 月至 2023 年 1 月的 MEDLINE 和 Embase,纳入 17 项研究共 2218 例慢性深静脉疾病患者,评估专用静脉支架的安全性与支架通畅率。12 个月一期通畅率 83%、一期辅助通畅率 90%、二期通畅率 95%,末次随访溃疡愈合率 68.8%,大出血 1.7%、小出血 3.2%。

要点

  • 12 个月一期通畅率 83%、一期辅助通畅率 90%、二期通畅率 95%。
  • 末次随访溃疡愈合率 68.8%(95%CI 52.0%-83.7%)。
  • 大出血 1.7%、小出血 3.2%,更常见于接受 Hybrid 干预的患者。

核心结论

  • 使用专用静脉支架进行深静脉支架置入是治疗慢性深静脉狭窄和/或闭塞的安全技术。
  • 在本研究的局限性范围内,深静脉支架置入与良好的通畅率和症状改善相关。

研究设计与样本

  • 检索 MEDLINE 和 Embase 数据库 2010 年 1 月至 2023 年 1 月发表的相关文献。
  • 共纳入 17 项研究、2218 例患者。
  • 对支架通畅率、溃疡愈合、出血和 30 天支架内血栓形成进行 Meta 分析,以比例事件率呈现。
  • 与支架置入后症状和健康相关生活质量相关的结果采用叙述性描述。

主要发现

  • 62.7% 的患者存在血栓后狭窄或闭塞。
  • 大多数患者(78.6%)在支架置入前存在深静脉完全闭塞。
  • 共置入 11 种不同的专用静脉支架。
  • 12 个月时一期通畅率为 83%(95%CI 76%-90%),一期辅助通畅率为 90%(95%CI 85%-96%),二期通畅率为 95%(95%CI 92%-98%)。
  • 干预后健康相关生活质量显著改善;观察到疼痛、静脉性跛行和水肿改善。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This review summarizes the safety profile, stent patency, and clinical effectiveness of dedicated venous stents for the treatment of chronic deep venous disease. The approaches to stenting and post-procedural management of different vascular units are also explored. METHODS: The MEDLINE and Embase databases were searched for pertinent literature published from January 2010 to January 2023. Outcomes related to post-stenting symptoms and health-related quality of life were described narratively. A meta analysis was conducted to evaluate stent patency, ulcer healing, bleeding, and 30-day stent thrombosis, and these outcomes were presented as proportion event rates. RESULTS: Seventeen studies were identified comprising of 2218 patients. 62.7% of individuals had post-thrombotic stenosis or occlusion. The majority of patients (78.6%) were noted to have complete occlusions of their deep veins before stenting. Eleven different dedicated venous stents were deployed. At 12 months, the primary patency rate was 83% (95% confidence interval [CI]: 76%-90%), the primary-assisted patency rate was 90% (95% CI: 85%-96%), and the secondary patency rate was 95% (95% CI: 92%-98%). A significant improvement in health-related quality of life was demonstrated after intervention. In total, 68.8% (95% CI: 52.0%-83.7%) of ulcers healed at the last follow-up. The remaining symptomatic changes were described narratively; improvements in pain, venous claudication, and edema after stenting were observed. Seventeen deaths occurred, but none were linked to the stenting procedures. A total of 159 cases (7.2% of patients) of in-stent stenosis were observed, whereas 110 stents (5.0% of patients) were occluded. The incidence of major and minor bleeding was 1.7% (95% CI: 1.0%-2.5%) and 3.2% (95% CI: 1.3%-5.6%), respectively, more commonly seen in patients undergoing hybrid intervention. CONCLUSIONS: Deep venous stenting using dedicated venous stents is a safe technique to treat chronic deep venous stenosis and/or occlusion. Within the limitations of this study, deep venous stenting is associated with good patency rates and symptomatic improvement.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Badesha AS, Black SA, Khan G, et al. A meta-analysis of the medium- to long-term outcomes in patients with chronic deep venous disease treated with dedicated venous stents. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 38104855. doi:10.1016/j.jvsv.2023.101722

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。